Skip to content
U.S. Transhumanist Party – Official Website
  • Home
  • Posts
  • Values
  • Platform
  • Leadership
  • Advisors
  • Candidates
  • Highlights
  • FAQ
  • States & Allies
  • Free Membership
  • Facebook
  • Twitter
  • Search Icon

U.S. Transhumanist Party – Official Website

U.S. Transhumanist Party – PUTTING SCIENCE, HEALTH, & TECHNOLOGY AT THE FOREFRONT OF AMERICAN POLITICS

A List of Possible FDA Reforms – Compilation by Dan Elton

A List of Possible FDA Reforms – Compilation by Dan Elton

March 26, 2021 Dan Elton Comments 0 Comment

Daniel C. Elton, Ph.D.


I have ranked these according to my own perception of which have the most support among DC bureaucrats and members of congress.

  • Improving transparency. During the COVID-19 pandemic the public has been kept in the dark regarding how key decisions were made, such as the decision to issue an EUA for hydroxychloroquine, the decisions that pushed Pfizer’s EUA from early November to late December, and the decision to require additional Phase III data from AstraZeneca which delayed their EUA by at least 3-4 months. Currently the FDA keeps much of the information relevant to decision making confidential. In theory Freedom of Information Act (FOIA) requests can be used to obtain some information, but in practice FOIAs are slow-walked, may require litigation, and take years to resolve. There are many possible ways to increase transparency at the FDA, some of which are outlined in this recent article in STAT News. 18 specific recommendations can be found in this journal article from 2018. One of people referenced as a top candidate for FDA Commissioner, Joshua M. Sharfstein, is a poor choice when it comes to implementing other reforms but has been a leading voice calling for more transparency.
  • Reciprocity. If a drug/medication is approved by a regulatory agency in a different country which has equivalent standards to the FDA (for instance agencies in the UK or Japan, the European Medicines Agency (EMA), or Health Canada), it should automatically be approved by the FDA (and vice versa). Reciprocity would save both taxpayers and companies a lot of time and money. Imagine if the AstraZeneca vaccine had been approved on January 1st, a few days after the UK approved it. It’s easy to see that tens of thousands of lives would have been saved, especially when you consider it would have been given to the most at-risk first!Ā  In 2015 Senators Mike Lee and Ted Cruz introduced the RESULT Act, which is primarily focused on implementing reciprocity.
  • Making the agency independent from the executive branch. It’s hard to insulate the FDA from political concerns as long as Congress controls the FDA’s purse, but it could at least be removed from direct interference from the executive branch by making it an independent agency like the FCC or Federal Reserve. There seems to be wide support behind this idea right now and recently four former FDA commissioners all endorsed this idea in an interview.
  • Rolling reviews. It should not take 3-4 weeks from the submission of an EUA application until a decision is made, especially when thousands are dying every day while waiting for vaccines. According to Dr. Marty Makary, a professor of public health policy at the Johns Hopkins Bloomberg School of Public Health who has conducted over a hundred clinical studies, the FDA ā€œcould have done the approval in 24-48 hours without cutting any cornersā€. Likewise, the approval of drugs and therapies after Phase III trials have reached an endpoint should not take 6 – 18 months. While the FDA does engage in a back and forth with companies prior to when they submit their paperwork for an EUA or approval, they do not use rolling reviews. Due to their rolling review systems other countries like the UK were able issue EUAs for COVID-19 vaccines faster than the FDA. Rolling reviews should be the norm, and the submission and analysis of trial data should made as streamlined and as efficient as possible without compromising the integrity of the analysis.
  • Tiered approvals. Doctors who want to provide new drugs to at-risk patients currently have to wait 5-10 years for lengthy Phase III trials to conclude and then another 6 – 18 months for the FDA to carry out their review of the trial data. Tiered approvals would allow a lower level of approval after just Phases I and II, freeing up treatments to those who need them most.Ā The centrist Niskanen center has a white paper which suggests four levels of approval (see also their op-ed in The Hill).
  • Expansion of Right-to-Try. Federal right-to-try legislation was passed in 2018. However, it is very restrictive, and patients need to have met a number of strict requirements before they can try new medications and treatments, greatly limiting its utility.
  • Treating aging as a disease. Currently it is illegal to market an FDA-approved product as a treatment for aging. Even though aging is a harmful biological process, it is not considered a legitimate ā€œindicationā€ for a drug or therapy by the FDA. In other words, the FDA doesn’t view aging as a ā€œdiseaseā€ and therefore anti-aging treatments fall outside their mandate. Some specific aspects of aging are also not considered as legitimate indications. The FDA is currently operating in an inconsistent way as some conditions which are due to the aging process can are considered legitimate targets, such as osteoporosis and menopause, but others, like sarcopenia (age-related muscle loss /frailty), are not.Ā  Many experts, including David Sinclair, have spoken out about this issue. Some companies have found ways to get around the FDA’s restrictions, such as by using certain metabolic markers to track the degree of damage from aging. However, the impossibility of getting FDA approval for therapies that directly slow down or repair the damages from aging greatly dis-incentivizes industry R&D investment in this area.Ā  Fortunately, with advanced gene and stem-cell therapies on the horizon, the Congress and the FDA have already taken a few steps towards being able to review and approve anti-aging drugs and therapies. The 21st-Century CURES Act, for instance, mandated the creation of the Regenerative Medicine Advanced Therapy designation at the FDA.
  • Challenge trials in emergency situations. Many people, including a group of legislators, lobbied the FDA to give companies the go-ahead to do challenge trials, but there was no action. Thousands of volunteers for COVID-19 challenge trials signed up with 1daysooner.org but were unable to participate as they had wished to. As a result, data on vaccine efficacy was obtained much slower than it could have been.
  • Use of the proactionary principle for all drug & therapy approvals. The FDA should publish a transparent, quantitative, scientifically informed, and structured cost-benefit analysis for each regulatory action performed, which estimates the expected quality-adjusted life years (QALYs) saved versus risk of QALYs lost for both the action and inaction. The analysis should be made public, ideally sometime before the decision goes into effect. Crucially, the analysis should enumerate the risks and benefits of granting an approval and the risks and benefits of not granting it. See Max More’s overview of the proactionary principle and his chapter in The Transhumanist Reader, where he presents not just a principle but an entire framework for rational decision making. The key reform here is to make it mandatory that decision making at the FDA be highly structured and quantitative so it under less sway from political concerns and cognitive biases. If such a framework for rational decision making was in place it’s unlikely the FDA would have decided to delay Pfizer’s Emergency Use Authorization (EUA) from early November to December 11th, a decision which cost tens of thousands of American lives.
  • Free to Choose Medicine with a Trade-off Evaluation Database.Ā  In brief, Free to Choose Medicine would create an additional track after Phases I and II to allow doctors to prescribe new therapies to at-risk patients who are unable or unwilling to participate in a Phase III trial. Patients in the Free-to-Choose Track would be mandated to submit data to a trade-off evaluation database, creating a trove of valuable real-world data (this could be genetic, biomarker, and adverse events data, for instance).Ā  See this excellent podcast interview with Bart Madden for more information.Ā 

Figure from Bart Madden, “Free to Choose Medicine“, The Heartland Institute

 

Dan Elton, Ph. D., is Director of Scholarship for the U.S. Transhumanist Party.Ā  You can find him on Twitter atĀ @moreisdifferent, where he accepts direct messages. If you like his content, check out his website and subscribe to his newsletter on Substack.Ā 


Statements
21st-Century CURES Act, Challenge trials, define aging as a disease, FDA, Free to choose medicine, proactionary principle, reciprocity, reform, regenerative medicine, regenerative medicine advanced therapies, Regenerative Medicine Advanced Therapy, right to try, rolling reviews, tiered approvals

Post navigation

PREVIOUS
Forecasting Whole-Brain Connectomics – A Kurzweilian Approach – Article by Dan Elton
NEXT
To Maryland Governor Larry Hogan: Liberate Vaccine Doses from the FDA! – Article by Dan Elton and Edward Hudgins

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Social Media

Constitution of the U.S. Transhumanist Party

Transhumanist Bill of Rights – Version 3.0

U.S. Transhumanist Party Facebook Feed

Victor Run Virtual Race – June 4-6, 2021

Free Transhumanist Symbols

Guidelines for Community Conduct

SUBMIT A POST

Recent Posts

  • U.S. Transhumanist Party Virtual Enlightenment Salon with Zack Varkaris – November 27, 2022
  • U.S. Transhumanist Party Virtual Enlightenment Salon with Steele Archer – December 4, 2022
  • U.S. Transhumanist Party Virtual Enlightenment Salon with Tom Ross and Zack Kopp – December 11, 2022
  • The Ethics and Implications of Indefinite Life Extension – Gennady Stolyarov II – Compilation Stream
  • Futuristic Neoclassical Music – Virtual Concert I – Gennady Stolyarov II and Jason Geringer – December 25, 2022
  • Rational Philosophy, Objective Morality, and Free Will – Gennady Stolyarov II – Compilation Stream
  • U.S. Transhumanist Party Virtual Enlightenment Salon with Nonso Nolly – January 8, 2023
  • U.S. Transhumanist Party Virtual Enlightenment Salon with Ian Hale – January 15, 2023
  • Virtual Enlightenment Salon on Hereditary Religion and the Dangers of Religious Indoctrination – January 22, 2023
  • U.S. Transhumanist Party General Discussion Thread for 2023
  • U.S. Transhumanist Party Chairman’s Sixth Anniversary and 2023 New Year’s Message
  • My Smart Stick Invention Prototype – Article by Nonso Nolly
  • Transhumanism: The Challenges of Techno-Scientific Power and Sociological Approach to African Backwardness – Article by Siba Tcha-Mouza
  • The Age of Deferred Aging – Article by J. Lund
  • U.S. Transhumanist Party and Nevada Transhumanist Party Positions on 2022 Nevada Ballot Questions
  • The U.S. Transhumanist Party Endorses Daniel E. Twedt for City Council in Thousand Oaks, California
  • U.S. Transhumanist Party Vote on the Question of Endorsing Daniel E. Twedt for City Council in Thousand Oaks, California
  • Constitution of the New York Transhumanist Party
  • U.S. Transhumanist Party to Participate in RAADfest 2022
  • U.S. Transhumanist Party Regional Liaison Spotlights: Celeste Castaldo and Dinorah Delfin

Recent Comments

  • Dan Kilian on Benefit for U.S. Transhumanist Party Members: Discounts Offered for Treatments from AmpliCell Medical
  • Cheryl Knepper on The U.S. Transhumanist Party Endorses Daniel E. Twedt for City Council in Thousand Oaks, California
  • Carlos on U.S. Transhumanist Party Vote on the Question of Endorsing Daniel E. Twedt for City Council in Thousand Oaks, California
  • Gennady Stolyarov II on Constitution of the New York Transhumanist Party
  • Daniel on U.S. Transhumanist Party Vote on the Question of Endorsing Daniel E. Twedt for City Council in Thousand Oaks, California

Archives

  • January 2023 (11)
  • December 2022 (2)
  • November 2022 (2)
  • October 2022 (3)
  • August 2022 (3)
  • July 2022 (2)
  • May 2022 (6)
  • March 2022 (3)
  • February 2022 (4)
  • January 2022 (7)
  • December 2021 (11)
  • November 2021 (4)
  • October 2021 (5)
  • September 2021 (2)
  • August 2021 (2)
  • July 2021 (4)
  • June 2021 (2)
  • May 2021 (6)
  • April 2021 (7)
  • March 2021 (4)
  • February 2021 (5)
  • January 2021 (6)
  • December 2020 (10)
  • November 2020 (4)
  • October 2020 (2)
  • September 2020 (1)
  • August 2020 (4)
  • July 2020 (5)
  • June 2020 (6)
  • May 2020 (3)
  • April 2020 (3)
  • March 2020 (6)
  • February 2020 (1)
  • January 2020 (6)
  • December 2019 (3)
  • November 2019 (2)
  • October 2019 (9)
  • September 2019 (10)
  • August 2019 (12)
  • July 2019 (18)
  • June 2019 (17)
  • May 2019 (12)
  • April 2019 (8)
  • March 2019 (12)
  • February 2019 (7)
  • January 2019 (13)
  • December 2018 (9)
  • November 2018 (5)
  • October 2018 (9)
  • September 2018 (5)
  • August 2018 (10)
  • July 2018 (13)
  • June 2018 (14)
  • May 2018 (8)
  • April 2018 (8)
  • March 2018 (10)
  • February 2018 (15)
  • January 2018 (17)
  • December 2017 (8)
  • November 2017 (17)
  • October 2017 (19)
  • September 2017 (11)
  • August 2017 (11)
  • July 2017 (16)
  • June 2017 (15)
  • May 2017 (10)
  • April 2017 (7)
  • March 2017 (8)
  • February 2017 (16)
  • January 2017 (8)
  • December 2016 (6)
  • November 2016 (5)

Categories

  • Allied Projects
  • Announcements
  • Art
  • Candidates
  • Discussion Panels
  • Distributed Computing
  • Exposure Periods
  • Foreign Ambassadors
  • General Discussion
  • Guest Articles
  • Inclusion
  • Interviews
  • Official Ballots
  • Petitions
  • Platform
  • Presentations
  • Press Releases
  • Research
  • Sample Ballots
  • Science Fiction
  • Statements
  • Tolerance
  • Virtual Enlightenment Salons
  • Vote Results
  • Working Groups
© 2023   Copyright - U.S. Transhumanist Party - All Rights Reserved | WordPress design: Art Ramon Paintings